Literature DB >> 22140234

Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study.

Lori B Daniels1, Paul Clopton, Mihael Potocki, Christian Mueller, James McCord, Mark Richards, Oliver Hartmann, Inder S Anand, Alan H B Wu, Richard Nowak, W Frank Peacock, Piotr Ponikowski, Martin Mockel, Christopher Hogan, Gerasimos S Filippatos, Salvatore Di Somma, Leong Ng, Sean-Xavier Neath, Robert Christenson, Nils G Morgenthaler, Stefan D Anker, Alan S Maisel.   

Abstract

AIMS: Midregional pro atrial natriuretic peptide (MR-proANP) is useful for diagnosing acute heart failure (HF) in patients presenting to the Emergency Department with dyspnoea. Optimal interpretation of MR-proANP requires understanding of how various demographic variables influence its levels and performance as a diagnostic marker. We sought to determine how age, race, sex, and body mass index (BMI) affect the levels and interpretation of MR-proANP for the diagnosis of acute HF. METHODS AND
RESULTS: The Biomarkers in Acute Heart Failure (BACH) study was an international 15-centre study of 1641 patients presenting to the Emergency Department with acute dyspnoea. Of these, 1352 had complete information on age, race, sex, and BMI. MR-proANP levels increased with age and were higher in men and in patients with lower BMI. MR-proANP performed better as a diagnostic marker in younger individuals and in blacks compared with whites. Despite this, MR-proANP at the recommended cut-off point of 120 pmol/L was >90 % sensitive in ruling out the diagnosis of acute HF in all subgroups of patients except white subjects <50 years old.
CONCLUSION: Age, race, sex, and BMI affect MR-proANP levels to various degrees. However, the diagnostic performance of the recommended cut-off point of 120 pmol/L to rule out acute HF was robust across most subgroups. Although both sex and BMI affected MR-proANP levels, they did not alter its overall diagnostic performance. Lower cut-off points for MR-proANP could be considered in younger patients and in patients with a higher BMI, to optimize diagnostic sensitivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22140234     DOI: 10.1093/eurjhf/hfr157

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

Review 1.  Cardiac biomarkers: new tools for heart failure management.

Authors:  Navaid Iqbal; Bailey Wentworth; Rajiv Choudhary; Alejandro De La Parra Landa; Benjamin Kipper; Arrash Fard; Alan S Maisel
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

2.  Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study.

Authors:  Deepak K Gupta; James A de Lemos; Colby R Ayers; Jarett D Berry; Thomas J Wang
Journal:  JACC Heart Fail       Date:  2015-06-10       Impact factor: 12.035

3.  Differences in Natriuretic Peptide Levels by Race/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis).

Authors:  Deepak K Gupta; Lori B Daniels; Susan Cheng; Christopher R deFilippi; Michael H Criqui; Alan S Maisel; Joao A Lima; Hossein Bahrami; Philip Greenland; Mary Cushman; Russell Tracy; David Siscovick; Alain G Bertoni; Valentina Cannone; John C Burnett; John Jeffrey Carr; Thomas J Wang
Journal:  Am J Cardiol       Date:  2017-06-30       Impact factor: 2.778

Review 4.  Cardiovascular biomarkers and sex: the case for women.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  Nat Rev Cardiol       Date:  2015-07-07       Impact factor: 32.419

5.  Diagnostic value of novel biomarkers for heart failure : A meta-analysis.

Authors:  Z Huang; J Zhong; Y Ling; Y Zhang; W Lin; L Tang; J Liu; S Li
Journal:  Herz       Date:  2018-04-26       Impact factor: 1.443

6.  Biomarkers in Acute Heart Failure - Cardiac And Kidney.

Authors:  A Mark Richards
Journal:  Card Fail Rev       Date:  2015-10

7.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

8.  Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Lori B Daniels; Paul Clopton; Christopher R deFilippi; Otto A Sanchez; Hossein Bahrami; Joao A C Lima; Russell P Tracy; David Siscovick; Alain G Bertoni; Philip Greenland; Mary Cushman; Alan S Maisel; Michael H Criqui
Journal:  Am Heart J       Date:  2015-09-28       Impact factor: 4.749

9.  Effects of elevation of ANP and its deficiency on cardiorenal function.

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Kristen Winsor; Gregory R Blass; Denisha R Spires; Elizaveta Sarsenova; Iuliia Polina; Adrian Zietara; Mark Paterson; Alison J Kriegel; Alexander Staruschenko
Journal:  JCI Insight       Date:  2022-05-09

Review 10.  Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs.

Authors:  Sam L Teichman; Alan S Maisel; Alan B Storrow
Journal:  Crit Pathw Cardiol       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.